Last reviewed · How we verify
Wydase (HYALURONIDASE)
Hyaluronidase increases tissue permeability by breaking down hyaluronic acid, promoting the diffusion and absorption of injected fluids.
At a glance
| Generic name | HYALURONIDASE |
|---|---|
| Sponsor | Baxter |
| Drug class | Endoglycosidase |
| Target | hyaluronic acid |
| Modality | Enzyme |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 1950 |
| Annual revenue | 900 |
Mechanism of action
Hyaluronidase works by hydrolyzing hyaluronic acid, a component of connective tissue. This process reduces the viscosity of the tissue, allowing for better diffusion and absorption of injected substances or localized fluids.
Approved indications
- Subcutaneous Fluid Administration
- Dispersion and Absorption of Injected Drugs
- Subcutaneous Urography
Common side effects
- Lagophthalmos
- Parophthalmia
- Purtscher retinopathy
- Conjunctival oedema
- Product administered at inappropriate site
- Exophthalmos
- Deep vein thrombosis postoperative
- Local anaesthetic systemic toxicity
- Myopathy toxic
- Macular ischaemia
- Autoimmune disorder
- Strabismus
Drug interactions
- Furosemide
- Benzodiazepines
- Phenytoin
- Dopamine
- Alpha agonist drugs
- Local anesthetics
- Salicylates
- Cortisone
- Adrenocorticotropic hormone (ACTH)
- Estrogens
- Antihistamines
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma (PHASE2)
- Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial (PHASE2)
- Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse (PHASE2)
- A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments (PHASE3)
- Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma (PHASE3)
- Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma (PHASE3)
- Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Wydase CI brief — competitive landscape report
- Wydase updates RSS · CI watch RSS
- Baxter portfolio CI